Plasma gelsolin levels in patients with liver disorders

用硫酸铵沉淀、DEAE层析、Affi-Gel Blue层析和苯基层析纯化人血浆凝溶胶蛋白，并注射兔血浆制备抗血清，以聚苯乙烯微球为固相，牛肠碱性磷酸酶为标记酶，建立了人血浆凝溶胶蛋白的竞争性酶免疫分析法。正常人血浆凝溶胶蛋白水平范围为124至270 μ g/ml。在急性肝炎患者中，血浆凝溶胶蛋白水平在转氨酶和胆红素升高期间降低。在慢性肝炎患者中，凝溶胶蛋白水平没有明显变化，包括急性加重期。在肝细胞癌患者中，凝溶胶蛋白水平升高后，经动脉栓塞治疗前的值相比。

Human plasma gelsolin was purified by ammonium sulfate precipitatio DEAE chromatography, Affi-Gel Blue chromatography and phenyl chromatography Antisera against plasma gelsolin were raised in rabbits by injecting the purified protein.A competitive enzyme immunoassay for the measurement of human plasm gelsolin was developed, using polystyrene beads as a solid phase and bovine interstinal alkaline phosphatase as a marker enzyme. Plasma gelsolin levels in normal persons ranged from 124 to 270 g/ml. In a patient with acute hepatitis, plasma gelsolin levels decreased during the presence of transaminase and bilirubin elevations. In patients with chronic hepatitis, the gelsolin level did not change markedly, including the period of acute exacerbation. In patients with hepatocellular cancer, the gelsolin levels elevated after transarterial embolization in comparison with pretreatment values.